MedTrace Logo

Capsaicin for Post-stroke Dysphagia

NCT04470752 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2023-06-22

No results posted yet for this study

Summary

Randomised, double blind, Phase 2 Trial to evaluate the efficacy of oral Capsaicin in patients with post-stroke dysphagia in the (sub-)acute setting.

Conditions

  • Dysphagia, Late Effect of Stroke

Interventions

DRUG

Capsaicin 1% oral solution

Capsaicin 1.0 micrograms/ml

DRUG

InOrpha Solution

glycerol based suspension vehicle

Sponsors & Collaborators

  • Cantonal Hospital of Aarau, Switzerland

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Georg Kägi, MD

    lead OTHER

Principal Investigators

  • Georg kägi, Dr. med. · Cantonal Hospital St. Gallen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-24
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470752 on ClinicalTrials.gov